Caplacizumab was approved by Health Canada in 2020, but is not funded for use in Canada despite being a standard of care in peer nations. Caplacizumab is our only immediate defence against the potentially life-altering blood clots that characterize a TTP crisis. Standard treatments are designed to control the underlying mechanism of disease, but require time to take effect, time that aTTP patients do not have. Caplacizumab can shield patients from the formation of clots, giving standard therapies the time they need to kick-in. Caplacizumab saves lives and prevents disability.
If you would rather write your own letter to your Provincial Health Minister and local elected provincial representative (MPP or MLA), please click here for further instructions.